Lilly Calls It Quits On Pegilodecakin As Loxo Team Reorganizes Cancer R&D

 
• By Joseph Haas

Revealing that the pegylated IL-10 therapy acquired in the Armo buyout two years ago has failed a pair of Phase II NSCLC trials, Lilly said it plans no further studies with the drug. Trulicity and Taltz led Lilly’s continuing growth story.

Pruning of ornamental trees by scissors
Lilly said it has no plans for further trials of pegilodecakin and terminated three earlier-stage cancer candidates

More from Earnings

More from Business